London-based Webiny nabs €2.9 million to help developers build serverless solutions in minutes

EU-Startups

Charlotte Tucker (eu-startups.com)

London-based Webiny, an open-source platform providing developer tools, libraries, ready-made apps and processes specifically created for serverless development, has raised €2.9 million in a seed funding round led by Microsoft’s venture arm M12, with notable participation from Samsung Next, Cota Capital, Episode 1 and YCombinator.

Founded in 2019, Webiny was originally conceived in the context of a serverless content management system. However, the startup states that as users and customers began requesting to use its serverless platform for more, such as building full-stack applications, scalable and performant APIs and fully control the security aspects around those, they pivoted. Webiny became a platform to help companies adopt serverless within their organisations..

With feedback from hundreds of organisations that have tried out Webiny, they decided to split Webiny into 2 different products. The serverless CMS, from before, and a new serverless application framework focusing on building full-stack apps and GraphQL APIs.

Webiny’s serverless application framework provides developers with a performant and ready-made architecture running on fault-tolerant serverless infrastructure, designed to handle millions of users. Previously, to reach this level of performance, scalability and redundancy, organisations had to have entire teams of experts to build and manage such a solution, now, these capabilities are available within minutes.

Having now closed this funding round, the team will use the boost to develop its platforms further, and improve their documentation and developer experience.

Sven Al Hamad, CEO and co-founder, commented in a recent statement: “None of this would have been possible without a team that truly believes in our mission supported by our existing investors and advisors. It’s a combination of many great things that came together at the right point in time, fueled by the amazing support and feedback coming from our amazing community.”

Original Article

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs

BusinessLive

By BusinessLive

Upsized and oversubscribed Series B financing brings healthcare and science focused venture capital

Aims to support acceleration of clinical development of low-dose psilocybin in SUNHA and 5MeO-DMT in other neuro-psychiatric indications

OXFORD, England–(BUSINESS WIRE)–Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC) investors to fund its promising research programmes. The Series B financing was initially set at $50m and was upsized to $80m due to overwhelming interest from investors to support Beckley Psytech in broadening and accelerating the clinical development of its innovative research pipeline.

Beckley Psytech will use the proceeds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression. The funding will also support the expansion of the company’s pipeline with new, unique and proprietary psychedelic compounds.

The financing round is led by Integrated, a healthcare focused VC which partners with companies and entrepreneurs that are transforming the health and well-being of communities around the globe. The science-focused investor consortium includes Prime Movers Labs, which funds breakthrough scientific startups; Adage Capital Management LP, a Boston based institutional investor; Palo Santo; Delphi VC; Leafy Tunnel; Negev Capital; and existing investor Bicycle Day Ventures.

Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “My life’s passion has been to unlock the therapeutic potential of psychedelics as I believe these compounds could help millions of people around the world. The progress Beckley Psytech has made in attracting exceptional talent to the team and advancing our ambitious clinical development programmes over the past two years has been tremendously exciting. As we embark on our next phase of growth, our strong syndicate of expert investors will support us in bringing much-needed innovative treatments to patients suffering from neurological and psychiatric conditions.”

Jay Newmark, general partner of Integrated, commented: “Cosmo and his dedicated team at Beckley Psytech have created an exceptional research and development platform. Their highly differentiated approach, which treats not only large indications such as depression but also rare indications such as SUNHA, is allowing accelerated access to market. We deeply appreciate our value alignment with this team and eagerly anticipate their progress in improving access to these medicines.”

Dr Amy Kruse, partner, Prime Movers Lab, said: “It is nearly impossible to find a team with more experience in developing psychedelic medicines for neurological conditions than the one at Beckley Psytech. The COVID-19 pandemic brought mental health to the public’s attention in a profound way. The excitement around psychedelics in the mental health market is very real because they are transformative medicines that will soon make their way into the lives of millions of people who desperately need them.”

Original Article